Pharmacologic targeting of coagulation factors XII and XI by monoclonal antibodies reduces thrombosis in nitinol...

Area of Science:

• Biomedical Engineering
• Hematology
• Cardiovascular Research

Background:

• Cardiovascular implantable devices, like vascular stents, are vital for treating heart disease.
• Current antithrombotic therapies carry significant bleeding risks.
• Coagulation factors XI and XII are potential targets for safer antithrombotic strategies.

Purpose of the Study:

• To evaluate the efficacy of monoclonal antibodies targeting coagulation factors (F)XI and FXII.
• To assess their role in preventing thrombosis related to vascular devices.

Main Methods:

• Utilized a nonhuman primate model to study nitinol stent-related thrombosis.
• Examined the effects of function-blocking monoclonal antibodies against FXI and FXII.
• Tested under both arterial and venous flow conditions.

Main Results:

• Both FXI and FXII inhibition reduced markers of stent-induced thrombosis in vitro and ex vivo.
• FXI inhibition demonstrated superior effectiveness in mitigating thrombosis across varied flow conditions.

Conclusions:

• Inhibitors of the coagulation contact pathway show potential for clinical use with cardiovascular devices.
• Further research supports the translation of these findings for improved patient outcomes.